Keyword: Merck Sharpe & Dohme

Merck canceled its partnership with Samsung Bioepis for a Lantus biosimilar after facing hurdles with pricing and production costs.

England's cost watchdog has decided Merck’s blockbuster Keytruda is not a good treatment choice in Hodgkin lymphoma—at least not for all patients.

Merck's HPV shot Gardasil won approval in China, Lupin's Q4 sales in North America fell 13%, and China’s CANbridge gained a $25M series B.

Just how well Keytruda sales outside the U.S. are doing remain vague in Merck's Q1 update, despite the drugmaker believing it will boost revenue.